Publication

Molecular Imaging in Cancer Drug Development

Waaijer, S. J. H., Kok, I. C., Eisses, B., Schröder, C. P., Jalving, M., Brouwers, A. H., Lub-de Hooge, M. N. & de Vries, E. G. E., 25-Jan-2018, In : Journal of Nuclear Medicine. 59, 5, p. 726-732 8 p.

Research output: Contribution to journalEditorialAcademicpeer-review

Copy link to clipboard

Documents

  • Molecular Imaging in Cancer Drug Development

    Final publisher's version, 750 KB, PDF document

DOI

Developing new oncology drugs has increased since the improved understanding of cancer's complex biology. The oncology field has become the top therapeutic research area for new drugs. However, only a limited number of drugs entering clinical trials will be approved for use as standard of care for cancer patients. Molecular imaging is increasingly perceived as a tool to support go/no-go decisions early during drug development. It encompasses a wide range of techniques including radiolabeling a compound of interest followed by visualization with single photon emission computed tomography or positron emission tomography. Radiolabeling can be performed using a variety of radionuclides that are preferably matched to the compound based on size and half-life. Imaging can provide information on drug behavior in vivo, whole body drug target visualization, and heterogeneity in drug target expression. This review focuses on current applications of molecular imaging in the development of small molecules, antibodies, and anti-hormonal anticancer drugs.

Original languageEnglish
Pages (from-to)726-732
Number of pages8
JournalJournal of Nuclear Medicine
Volume59
Issue number5
Publication statusE-pub ahead of print - 25-Jan-2018

    Keywords

  • Journal Article

View graph of relations

ID: 54011647